Binding of the Epstein-Barr Virus to Human Platelets Causes the Release of Transforming Growth Factor-β

Journal of Immunology

Volumn 159, Issue 8, 1997, Pages 3984-3988

  Ahmad, Ali ^a   Menezes, José ^b  

^a UNIVERSITY OF MONTREAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3D RECEPTOR; MONOCLONAL ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; VIRUS RECEPTOR;

ARTICLE; BLOOD; DRUG ANTAGONISM; EPSTEIN BARR VIRUS; HUMAN; IMMUNOLOGY; KINETICS; METABOLISM; PHYSIOLOGY; THROMBOCYTE; TIME; VIROLOGY;

ANTIBODIES, MONOCLONAL; BLOOD PLATELETS; HERPESVIRUS 4, HUMAN; HUMANS; KINETICS; RECEPTORS, COMPLEMENT 3D; RECEPTORS, VIRUS; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 0031572589     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Isenberg, W. M., D. F. Bainton, E. F. Plow, H. M. Ginsberg, and L. F. Brass, and M. A. Schuman. 1995. Cell biology of platelets and endothelial cells. In Haematology: Basic Principles and Practice, 2nd Ed. R. Hoffman, E. J. Benz, Jr., S. J. Shattil, B. Furie, H. J. Cohen, and L. E. Silberstein, eds. Churchill Livingstone, New York, p. 1516.
2. Page, C. P. 1988. The involvement of platelets in non-thrombotic processes. Trends Pharmacol. Sci. 9:66.
3. McCartney-Francis, N. L., and S. M. Wahl. 1994. Transforming growth factor β: a matter of life and death. J. Leukocyte Biol. 55:401.
4. 3, and localization of the cytotoxic system in membranes. J. Exp. Med. 166:489.
5. Joseph, M., C. Auriault, A. Capron, H. Vorng, and P. Viens. 1985. A new function for platelets: IgE-dependent killing of schistosomes. Nature 303:810.
6. Ibele, G. M., N. E. Kay, G. J. Johnson, and H. S. Jacob. 1985. Human platelets exert cytotoxic effects on human tumor cells. Blood 65:1252.
7. Yong, E. C., E. Y. Chi, T. R. Fritsche, and W. R. Henderson, Jr. 1991. Human platelet-mediated cytotoxicity against Toxoplasma gondii: role of thromboxane. J. Exp. Med. 173:65.
8. Sagawa, T., T. Kodama, A. Tominga, and M. Okada. 1990. Human platelets effectively kill K562 cells, a chronic myelogenic leukemic cell line, in vitro. Jpn. J. Cancer Res. 81:449.
9. McCrae, K. R., S. J. Shattil, and D. B. Cines. 1990. Platelet activation induces increased Fcγ receptor expression. J. Immunol. 144:3920.
10. McEver, M. R. 1994. Selectins. Curr. Opin. Immunol. 6:75.
11. 3d/EBV receptor (CR2). Eur. J. Immunol. 17:515.
12. 3d receptor CR2. Proc. Natl. Acad. Sci. USA 81:4510.
13. 3d receptor of human B lymphocytes, is also the Epstein-Barr virus receptor. Proc. Natl. Acad. Sci. USA 82:1490.
14. 3d complement receptor (CR2). J. Virol. 55:347.
15. Rickinson, A. B., and E. Kieff. 1996. Epstein-Barr virus. In Fields Virology, 3rd Ed., Vol. II. B. N. Fields, D. M. Knipe, and P. M. Howley, eds. Lippincott-Raven Publishers, New York, p. 2397.
16. Alsip, G. R., Y. Ench, C. V. Sumaya, and R. N. Boswell. 1988. Increased Epstein-Barr virus DNA in oropharyngeal secretions from patients with AIDS, AIDS-related complex or asymptomatic human immunodeficiency virus infections. J. Infect. Dis. 157:1072.
17. Birx, D. L., R. R. Redfreld, and G. Tosato. 1986. Defective regulation of Epstein-Barr virus infection in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related disorders. N. Engl. J. Med. 314:874.
18. Greenspan, J. S., D. Greenspan, E. T. Lennette, D. I. Abrams, M. A. Conant, V. Peterson, and U. K. Freese. 1985. Replication of Epstein-Barr virus within the epithelial cells of oral "hairy" leukoplakia, an AIDS-associated lesion. N. Engl. J. Med. 313:1564.
19. Testi, R., F. Pulcinelli, L. Frati, P. P. Gazzaniga, and A. Santoni. 1990. CD69 is expressed on platelets and mediates platelet activation and aggregation. J. Exp. Med. 172:701.
20. Miller, G., and M. Lipman. 1973. Release of infectious Epstein-Barr viruses by transformed marmoset leukocytes. Proc. Natl. Acad. Sci. USA 70:190.
21. Hinuma, Y., and J. T. Grace. 1967. Cloning of immunoglobulin-producing leukemic and lymphoma cells in long term cultures. Proc. Soc. Exp. Biol. Med. 124:107.
22. Menezes, J., W. Leibold, and G. Klein. 1975. Biological differences between Epstein-Barr virus strains with regard to lymphocyte transforming ability, super-infection and antigen induction. Exp. Cell. Res. 92:478.
23. Lotz, M., J. Kekow, and D. A. Carson. 1990. Transforming growth factor-β and cellular immune responses in synovial fluids. J. Immunol. 144:4189.
24. Daniel, W. N. 1991. Biostatislics: A foundation of Analysis in Health Sciences, 5th Ed. John Wiley & Sons, Toronto, p. 209.
25. Wilson, B. S., J. L. Platt, and N. E. Kay. 1985. Monoclonal antibodies to the 140,000 mol. wt glycoprotein of B lymphocyte membranes (CR2 receptor) initiates proliferation of B cells in vitro. Blood 66:824.
26. Cayrol, C., and E. K. Flemington. 1995. Identification of cellular target genes of the Epstein-Barr virus transactivator Zta: activation of transforming growth factor beta igh3 (TGF-β igh3) and TGF-β1. J. Virol. 69:4206.
27. Allen, J. B., H. L. Wong, P. M. Guyre, G. L. Simon, and S. M. Wahl. 1991. Association of circulating receptor FcγRIII-positive monocytes in AIDS patients with elevated levels of transforming growth factor β. J. Clin. Invest. 87:1773.
28. Preiksaitis, J. K., F. Diaz-Mitoma, F. Mirzayans, S. Roberts, and D. L. Tyrrell. 1992. Quantitative oropharyngeal Epstein-Barr virus shedding in renal and cardiac transplant recipients: relationship to immunosuppressive therapy, serologic responses and risk of post-transplant lymphoproliferative disorder. J. Infect. Dis. 166:986.
29. Radel, E. G., and J. B. Schoor. 1963. Thrombocytopenic purpura with infectious mononucleosis. J. Pediatr. 63:46.
30. Scadden, D. T., L. I. Zon, and J. E. Groopman. 1989. Pathophysiology and management of HIV-associated hematologic disorders. Blood 74:1455.
31. 3d complement fragment. Annu. Rev. Immunol. 6:85.
32. 3d receptor (CR2) reacts with p53, a cellular antioncogene-encoded membrane phosphoprotein: detection by polyclonal anti-idiotypic anti-CR2 antibodies. Proc. Natl. Acad. Sci. USA 86:10054.
33. 3d receptor (CR2) with p68, a calcium-binding protein present in normal but not in transformed B lymphocytes. J. Immunol. 147:1286.
34. Fearon, D. T., and R. H. Carter. 1995. The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity. Annu. Rev. Immunol. 13:127.
35. 3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271:348.
36. Carter, R. H., and D. T. Fearon. 1992. CD19: Lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 256:105.
37. Birkenbach, M., X. Tong, L. E. Bradbury, T. F. Tedder, and E. Kieff. 1992. Characterization of an Epstein-Barr virus receptor on human epithelial cells. J. Exp. Med. 176:1405.
38. + (cytotoxic/suppressor) T lymphocytes. J. Gen. Virol. 71:379.
39. Patel, P. C., and J. Menezes. 1981. Epstein-Barr virus (EBV) lymphoid cell interactions. I. Quantification of EBV particles required for the membrane immunofluorescence assay and the comparative expression of EBV receptors on different human B, T and null cell lines. J. Gen. Virol. 53:1.
40. Nemerow, G. R., M. E. McNaughton, and N. R. Cooper. 1985. Binding of monoclonal antibody to Epstein-Barr virus (EBV)/CR2 receptor induces activation and differentiation of human B lymphocytes. J. Immunol. 135:3068.
41. Tanner, J. E., C. Alfieri, T. A. Chatila, and F. Diaz-Mitoma. 1996. Induction of interleukin 6 after stimulation of human B-cell CD21 by Epstein-Barr virus glycoproteins gp350 and gp220. J. Virol. 70:570.
42. Gosselin, J., J. Menezes, M. D'Addario, J. Hiscott, L. Flamand, G. Lamoureux, and D. Oth. 1991. Inhibition of tumor necrosis factor-alpha transcription by Epstein-Barr Virus. Eur. J. Immunol 21:203.
43. Todd, S. C., and D. Tsoukas. 1996. EBV induces proliferation of immature human thymocytes in an IL-2-mediated response. J. Immunol. 150:4217.